Clinical Trial Update: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib in advanced or recurrent uterine cancer has completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Sarcoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-10